Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success
Commercial Strategy In Place Early
Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.
You may also be interested in...
‘Pipeline In A Product’ Nipocalimab Starts Delivering For J&J
Johnson & Johnson splashed a lot of cash to get hold of the FcRn inhibitor and is exploring nearly a dozen indications. Nipocalimab has advanced in one of those this week, severe hemolytic disease of the fetus and newborn.
Argenx Enters Japan With Smooth Approval – How Was It Possible?
Belgian bioventure Argenx has made an unusually smooth commercial entry to Japan with Vyvgart almost as fast as the launch of the myasthenia gravis drug in the US. Its founder admits it was a “bold move” for a European pharma company and revealed how the unexpected entrance was made possible.
Analysts Admire Argenx's Vyvgart Launch
The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.